Jorge Fortun, MD
Ophthalmology · Palm Beach Gardens, FLNPI 1184736464
Payments from drug & device makers
Across 697 payments — averaging $1348.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$158K
- Apellis Pharmaceuticals, Inc.$151K
- Alimera Sciences, Inc.$126K
- Astellas Pharma US Inc$104K
- Genentech, Inc.$83K
- Regeneron Healthcare Solutions, Inc.$76K
- plus $241K from 23 others
Across 2 payments — averaging $2966.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alimera Sciences, Inc.$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 90 | $158,423 |
| Apellis Pharmaceuticals, Inc. | 119 | $150,676 |
| Alimera Sciences, Inc. | 61 | $126,350 |
| Astellas Pharma US Inc | 74 | $103,877 |
| Genentech, Inc. | 12 | $82,740 |
| Regeneron Healthcare Solutions, Inc. | 82 | $76,379 |
| Dutch Ophthalmic, USA | 40 | $56,885 |
| ANI Pharmaceuticals, Inc. | 24 | $41,976 |
| Alcon | 31 | $29,971 |
| AbbVie(2 entities) | 39 | $25,229 |
| Carl Zeiss Meditec, Inc. | 25 | $22,296 |
| Dutch Ophthalmic Research Center (international) B.v. | 2 | $20,008 |
| Carl Zeiss Meditec USA, Inc. | 14 | $13,253 |
| Genentech USA, Inc. | 27 | $12,077 |
| Eyepoint US, Inc. | 18 | $9,879 |
| Beaver-visitec International, Inc. | 6 | $4,887 |
| Bausch & Lomb Americas Inc. | 8 | $2,077 |
| Oculus Surgical Inc. | 5 | $1,240 |
| Ocular Therapeutix, Inc. | 3 | $432 |
| Regeneron | 3 | $266 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $210 |
| Notal Vision, Inc. | 1 | $120 |
| Pfizer | 1 | $115 |
| Sun Pharmaceutical Industries Inc. | 1 | $105 |
| Harrow Eye, LLC | 2 | $62 |
| Halozyme Inc | 3 | $54 |
| Biogen | 1 | $28 |
| Baudax Bio Inc. | 1 | $23 |
| Coherus Oncology, Inc. | 1 | $22 |
How this compares
$939,658 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Palm Beach Gardens
- Mark MilnerPalm Beach Gardens$1.2M
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.